Hexvix, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix, a drug used for bladder cancer diagnosis, has been included in the 2022 edition of the Lecheng Global Specialty Drug Insurance Specialty Drug List.

Lecheng Global Specialty Drug Insurance is an inclusive supplementary commercial medical insurance policy jointly underwritten by a number of well-known domestic insurance companies and supervised by the Hainan Office of China Banking and Insurance Regulatory Commission under the guidance of the Bo'ao Lecheng International Medical Tourism Pilot Zone Administration and the Medical Security Bureau of Hainan Province. With a drug list covering 40 specialty drugs on the market in China and 60 overseas specialty drugs, the policy is designed to boost the development of a multi-tiered medical security system in Hainan by strengthening its efficient combination and coordination with basic medical insurance, critical illness insurance and medical aid policies, so as to effectively lighten the burden of medical care for the insured and further address people's diverse medical and health care needs on different levels.

Hexvix has been approved in the United States and many European countries. The combined use of Hexvix and blue light cystoscopy (BLC) for the management of non-muscle invasive bladder cancer (NMIBC) has been included in the global expert consensus guidelines and Chinese Urological Association Guideline.